Abstract
Abstract
Diabetic nephropathy (DN) is one of the major long term hurdles of diabetes mellitus. Type 1 diabetes affects 30% of individuals while type 2 diabetes mellitus (T2DM) affects 40% of individuals. DM is now used in a greater number of anti-diabetic medications, but there are a number of disadvantages, including drug resistance, decreased effectiveness, negative effects, and even toxicity. The anti-diabetic alternative medications for isoflavnoid compounds are used for the treatment of diseases and disorders with their fewer side effects, easy availability, and low cost. Hence, the present study was Prunetin (PRU) an methoxyflavonoids from the isoflavone family. In this compound has been used for in silico screening for diabetic nephropathy potential, were performed with four target proteins: insulin degrading enzyme (IDE), glucose transporter 2 (GLUT2), kidney injury molecule 1 (KIM-1), and glutamine-fructose-6-phosphate aminotransferase (GFPT). ChemSpider and NCBI PubChem databases software were used for ligand preparation in a molecular docking study. In silico druglikeness, ADME, and toxicity studies prediction of PRU using the Swiss ADME server and ProTox-II web server. Molecular docking studies for targeted proteins with drug candidates that have inhibitory action by minimum binding energy and affinity score. Hence the research suggested that PRU could be a potential diabetic nephropathy drug.
Publisher
Research Square Platform LLC
Reference21 articles.
1. 1. Ramanjaneyulu M, Kumar KA, Kumar MS, Reddy S, Kara D, Mukthala P, Raj R, Madhu C. Target identification and validation for diabetic nephropathy using molecular docking studies. Der Pharma Chemica. 2013;5(6):353 − 63.
2. 2. Hussain S, Jamali MC, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clinical Epidemiology and Global Health. 2021 Jan 1;9:2–6.
3. 3. Arumugam G, Manjula P, Paari N. A review: Anti diabetic medicinal plants used for diabetes mellitus. Journal of Acute Disease. 2013 Jan 1;2(3):196–200.
4. 4. Dey L, Attele AS, Yuan CS. Alternative therapies for type 2 diabetes. Alternative medicine review. 2002 Feb 1;7(1):45–58.
5. 5. Kooti W, Moradi M, Ali-Akbari S, Sharafi-Ahvazi N, Asadi-Samani M, Ashtary-Larky D. Therapeutic and pharmacological potential of Foeniculum vulgare Mill: a review. Journal of HerbMed Pharmacology. 2015 May 26;4(1):1–9.